Resistance of Asian Cryptococcus neoformans serotype a is confined to few microsatellite genotypes

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Pan, Weihua ^a   Khayhan, Kantarawee ^b,c,d   Hagen, Ferry ^b,c   Wahyuningsih, Retno ^e,f   Chakrabarti, Arunaloke ^g   Chowdhary, Anuradha ^h   Ikeda, Reiko ⁱ   Taj Aldeen, Saad J ^j   Khan, Ziauddin ^k   Imran, Darma ^e,l   Sjam, Ridhawati ^e   Sriburee, Pojana ^m   Liao, Wanqing ^a   Chaicumpar, Kunyaluk ⁿ   Ingviya, Natnicha ^o   Mouton, Johan W ^p,q   Curfs Breuker, Ilse ^p   Boekhout, Teun ^b,c   Meis, Jacques F ^p,q   Klaassen, Corné H W ^p  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF PHAYAO   (Thailand)

^e UNIVERSITY OF INDONESIA   (Indonesia)

^f CHRISTIAN UNIVERSITY OF INDONESIA   (Indonesia)

^g POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^h UNIVERSITY OF DELHI   (India)

ⁱ MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^j HAMAD MEDICAL CORPORATION   (Qatar)

^k KUWAIT UNIVERSITY   (Kuwait)

^l CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^m Faculty of Medicine Chiang Mai University   (Thailand)

ⁿ KHON KAEN UNIVERSITY   (Thailand)

^o PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^p CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^q RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; MICROSATELLITE DNA;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INDONESIA; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEROTYPE; ASIA; GENETICS; MICROBIOLOGY; POLYMERASE CHAIN REACTION; SEROTYPING;

CRYPTOCOCCUS NEOFORMANS VAR. GRUBII; FILOBASIDIELLA NEOFORMANS; FUNGI;

ASIA; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FLUCYTOSINE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HUMANS; MICROSATELLITE REPEATS; POLYMERASE CHAIN REACTION; SEROTYPING;

EID: 84858111081     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032868     Document Type: Article

References (55)

1. Bovers M, Hagen F, Boekhout T, (2008) Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Revista Iberoamericana de Micologia 25: S4-12.
2. Lin X, Heitman J, (2006) The biology of the Cryptococcus neoformans species complex. Annual Review of Microbiology 60: 69-105.
3. Springer DJ, Chaturvedi V, (2010) Projecting global occurrence of Cryptococcus gattii. Emerging Infectious Diseases 16: 14-20.
4. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clinical Infectious Diseases 50: 291-322.
5. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
6. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, et al. (2008) Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerging Infectious Diseases 14: 755-762.
7. Xu J, Manosuthi W, Banerjee U, Zhu LP, Chen J, et al. (2011) Cryptococcosis in Asia. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A, editors. Cryptococcus from human pathogen to model yeast Washington DC ASM press pp. 287-297.
8. Shen YZ, Qi TK, Ma JX, Jiang XY, Wang JR, et al. (2007) Invasive fungal infections among inpatients with acquired immune deficiency syndrome at a Chinese university hospital. Mycoses 50: 475-480.
9. Choi YH, Ngamskulrungroj P, Varma A, Sionov E, Hwang SM, et al. (2010) Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Research 10: 769-778.
10. Day JN, Hoang TN, Duong AV, Hong CTT, Diep PT, et al. (2011) Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VNI. Journal of Clinical Microbiology 49: 658-664.
11. Diaz MR, Boekhout T, Kiesling T, Fell JW, (2005) Comparative analysis of the intergenic spacer regions and population structure of the species complex of the pathogenic yeast Cryptococcus neoformans. FEMS Yeast Research 5: 1129-1140.
12. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, et al. (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proceedings of the National Academy of Sciences of the United States of America 101: 17258-17263.
13. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, et al. (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Medical Mycology 47: 561-570.
14. Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, et al. (2001) Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 147: 891-907.
15. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, et al. (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Medical Mycology 47: 561-570.
16. de Valk HA, Meis JFGM, Klaassen CHW, (2007) Microsatellite based typing of Aspergillus fumigatus: strengths, pitfalls and solutions. Journal of Microbiological Methods 69: 268-272.
17. Illnait-Zaragozi M-T, Martinez-Machin GF, Fernandez-Andreu CM, Boekhout T, Meis JF, et al. (2010) Microsatellite typing of clinical and environmental Cryptococcus neoformans var. grubii isolates from Cuba shows multiple genetic lineages. PloS One 5: e9124-e9124.
18. Rudramurthy SM, de Valk HA, Chakrabarti A, Meis JFGM, Klaassen CHW, (2011) High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellites. PloS One 6: e16086-e16086.
19. Klaassen CHW, (2009) MLST versus microsatellites for typing Aspergillus fumigatus isolates. Medical Mycology 47 (Suppl 1): S27-33-S27-33.
20. Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Sousa A, et al. (2003) Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. Journal of Clinical Microbiology 41: 5623-5632.
21. Kwon-Chung KJ, Polacheck I, Bennett JE, (1982) Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). Journal of Clinical Microbiology 15: 535-537.
22. Hagen F, Illnait-Zaragozi M-T, Bartlett KH, Swinne Dl, Geertsen E, et al. (2010) In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrobial Agents and Chemotherapy 54: 5139-5145.
23. Bovers M, Hagen F, Kuramae EE, Diaz MR, Spanjaard L, et al. (2006) Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res 6: 599-607.
24. Barreto de Oliveira MT, Boekhout T, Theelen B, Hagen F, Baroni FA, et al. (2004) Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. Journal of Clinical Microbiology 42: 1356-1359.
25. Clinical Laboratory Standards Institute (2008) M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard Wayne, PA.
26. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clinical Infectious Diseases 50: 291-322.
27. Nguyen MH, Yu CY, (1998) In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and-resistant Cryptococcus neoformans isolates. Antimicrobial Agents and Chemotherapy 42: 471-472.
28. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, et al. (2005) In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. Journal of Clinical Microbiology 43: 3807-3810.
29. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, et al. (2004) In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagnostic Microbiology and Infectious Disease 48: 201-205.
30. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, et al. (2005) Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). Journal of Clinical Microbiology 43: 2163-2167.
31. Souza LKH, Souza Junior AH, Costa CR, Faganello J, Vainstein MH, et al. (2010) Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil. Mycoses 53: 62-67.
32. Simpson EH, (1949) Measurement of Diversity. Nature 163: 688-688.
33. Illnait-Zaragozi MT, Martinez-Machin GF, Fernandez-Andreu CM, Hagen F, Boekhout T, et al. (2010) Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infectious Diseases 10: 289-289.
34. Franzot SP, Hamdan JS, Currie BP, Casadevall A, (1997) Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. Journal of Clinical Microbiology 35: 2243-2251.
35. Jain N, Wickes BL, Keller SM, Fu J, Casadevall A, et al. (2005) Molecular epidemiology of clinical Cryptococcus neoformans strains from India. Journal of Clinical Microbiology 43: 5733-5742.
36. Meyer W, Marszewska K, Amirmostofian M, Igreja RP, Hardtke C, et al. (1999) Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 20: 1790-1799.
37. Simwami SP, Khayhan K, Henk DA, Aanensen DM, Boekhout T, et al. (2011) Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. PLoS Pathogens 7: e1001343-e1001343.
38. Sriburee P, Khayhan S, Khamwan C, Panjaisee S, Tharavichitkul P, (2004) Serotype and PCR-fingerprints of clinical and environmental isolates of Cryptococcus neoformans in Chiang Mai, Thailand. Mycopathologia 158: 25-31.
39. Sukroongreung S, Lim S, Tantimavanich S, Eampokalap B, Carter D, et al. (2001) Phenotypic switching and genetic diversity of Cryptococcus neoformans. J Clin Microbiol 39: 2060-2064.
40. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, et al. (2006) Global patterns of influenza a virus in wild birds. Science 312: 384-388.
41. Garcia-Hermoso D, Janbon G, Dromer F, (1999) Epidemiological evidence for dormant Cryptococcus neoformans infection. Journal of Clinical Microbiology 37: 3204-3209.
42. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, et al. (2001) Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107: E66-E66.
43. Casali AK, Goulart Lc, Rosa e Silva LvK, Ribeiro AM, Amaral AA, et al. (2003) Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Research 3: 405-415.
44. Currie BP, Freundlich LF, Casadevall A, (1994) Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. Journal of Clinical Microbiology 32: 1188-1192.
45. Delgado ACN, Taguchi H, Mikami Y, Myiajy M, Villares MCB, et al. (2005) Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas. Mycopathologia 159: 7-11.
46. Yamamoto Y, Kohno S, Koga H, Kakeya H, Tomono K, et al. (1995) Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki. Journal of Clinical Microbiology 33: 3328-3332.
47. Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, et al. (2001) Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrobial Agents and Chemotherapy 45: 3065-3069.
48. Illnait-Zaragozi M-T, Martinez GF, Curfs-Breuker I, Fernandez CM, Boekhout T, et al. (2008) In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrobial Agents and Chemotherapy 52: 1580-1582.
49. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, et al. (2009) Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 53: 309-311.
50. Chottanapund S, Singhasivanon P, Kaewkungwal J, Chamroonswasdi K, Manosuthi W, (2007) Survival time of HIV-infected patients with cryptococcal meningitis. Journal of the Medical Association of Thailand 90: 2104-2111.
51. Ganiem AR, Parwati I, Wisaksana R, van der Zanden A, van de Beek D, et al. (2009) The effect of HIV infection on adult meningitis in Indonesia: a prospective cohort study. AIDS 23: 2309-2316.
52. Perea S, Patterson TF, (2002) Antifungal resistance in pathogenic fungi. Clinical Infectious Diseases 35: 1073-1080.
53. Vermes A, Guchelaar HJ, Dankert J, (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy 46: 171-179.
54. Perfect JR, Cox GM, (1999) Drug resistance in Cryptococcus neoformans. Drug Resistance Updates 2: 259-269.
55. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764-1767.